Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17817
Title: Massive splenomegaly due to concurrent primary Epstein-Barr virus and cytomegalovirus infection in a patient on adalimumab.
Austin Authors: Ramasamy, Barathy Rani;Charles, Patrick G P ;Johnson, Douglas F;Frauman, Albert
Affiliation: Department of General Medicine, Austin Health, Heidelberg, Victoria, Australia
Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia
Department of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 1-Sep-2017
metadata.dc.date: 2017-09-01
Publication information: BMJ Case Reports 2017; 2017: bcr-2017-220184
Abstract: A 32-year-old man who was receiving adalimumab for seronegative rheumatoid arthritis presented with a 4-week history of fever, night sweats, fatigue, myalgias and diarrhoea. On examination, he had obvious splenomegaly but no lymphadenopathy or pharyngitis. Full blood count revealed mild neutropenia and significant lymphocytosis, with a blood film showing atypical lymphocytes. Liver function tests were mildly deranged with a mixed hepatitic and obstructive pattern. Ultrasound confirmed massive splenomegaly with a span of 21 cm in the long axis. Serological tests confirmed the presence of both primary Epstein-Barr virus and cytomegalovirus infections. The patient had his adalimumab withheld, was treated with supportive measures and improved over a period of 8 weeks. He remained well 5 months after the onset of illness with complete normalisation of blood count and a resolution of the splenomegaly.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17817
DOI: 10.1136/bcr-2017-220184
PubMed URL: 28864556
Type: Journal Article
Subjects: Infectious diseases
rheumatoid arthritis
unwanted effects / adverse reactions
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Dec 1, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.